Mantle Cell Mini Allo
Trial overview
Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma.
To assess the safety and efficacy of Reduced Intensity Conditioning (RIC) transplantation as part of the initial treatment of Mantle Cell Lymphoma (MCL).
Inclusion criteria
- At least 18 years of age and considered fit for a transplant by the treating physician
A confirmed diagnosis of MCL:
- MCL must be proven by a histological examination of representative material (lymph nodes or bone marrow) together with a typical immunophenotype CD5+, CD23-, Slgm
- Central review of histology is mandatory
- NB: Molecular/cytogenetic confirmation of diagnosis is desirable but not mandatory
- No concurrent serious medical condition that would preclude an allograft
- Evidence of PR/CR following prior therapy
- Staging diagnosis and staging to prove response
Exclusion criteria
- Relapsed or progressive disease
- Previous malignancy in the past 5 years, except non-melanoma skin tumours or stage 0 (in situ) cervical carcinoma
- Known serological positivity for HBV, HCV or HIV
- Patients with a history of a psychological illness or condition that in the opinion of the investigator may adversely affect compliance with planned therapy
Contact details
Other trials currently active for Mantle Cell Lymphoma
A Parallel Randomised Phase II Trial Of CHOP Chemotherapy With Or Without Bortezomib In Relapsed Mantle Cell Lymphoma